Overview
Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
Indication
For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
Associated Conditions
- Hypertension
- Mild Hypertension
- Moderate Essential Hypertension
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/13 | Not Applicable | Recruiting | |||
2018/04/13 | N/A | Recruiting | |||
2015/11/03 | Phase 4 | Completed | Lee's Pharmaceutical Limited | ||
2013/08/27 | Phase 3 | Completed | LG Life Sciences | ||
2012/01/27 | Phase 4 | Completed | Lee's Pharmaceutical Limited | ||
2010/08/12 | Phase 4 | Completed | Aarhus University Hospital | ||
2010/05/13 | Phase 2 | Completed | LG Life Sciences | ||
2010/03/26 | Phase 2 | Completed | |||
2007/11/27 | Phase 4 | UNKNOWN | Università degli Studi dell'Insubria | ||
2007/01/22 | Not Applicable | Terminated |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Lercanidipine Hydrochloride Tablets | 国药准字H20249816 | 化学药品 | 片剂 | 12/25/2024 | |
| Lercanidipine Hydrochloride Tablets | recordati s.p.a. | 国药准字HJ20160269 | 化学药品 | 片剂 | 4/25/2022 |
| Lercanidipine Hydrochloride Tablets | recordati s.p.a. | 国药准字HJ20160257 | 化学药品 | 片剂 | 4/25/2022 |
| Lercanidipine Hydrochloride Tablets | 国药准字H20243083 | 化学药品 | 片剂 | 1/23/2024 | |
| Lercanidipine Hydrochloride Tablets | 国药准字H20227008 | 化学药品 | 片剂 | 1/20/2022 | |
| Lercanidipine Hydrochloride Tablets | 国药准字H20103398 | 化学药品 | 片剂 | 8/4/2020 | |
| Lercanidipine Hydrochloride Tablets | recordati s.p.a. | 国药准字HJ20160258 | 化学药品 | 片剂 | 4/25/2022 |
| Lercanidipine Hydrochloride Tablets | 国药准字H20213023 | 化学药品 | 片剂 | 1/12/2021 | |
| Lercanidipine Hydrochloride Tablets | 国药准字H20203270 | 化学药品 | 片剂 | 6/17/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Help Us Improve
Your feedback helps us provide better drug information and insights.